FDA pan­el votes yes on In­di­v­ior’s opi­oid ad­dic­tion drug

In­di­v­ior’s (LON: IN­DV) ex­per­i­men­tal drug to fight opi­oid ad­dic­tion may soon get the green light from reg­u­la­tors fol­low­ing a near-unan­i­mous vote for ap­proval by an ad­vi­so­ry com­mit­tee.

The drug, called RBP-6000, is an in­jectable ver­sion of buprenor­phine to treat opi­oid use dis­or­der. The med­i­cine is meant to be used as part of a treat­ment plan that in­cludes coun­sel­ing and psy­choso­cial sup­port.

Con­sid­er­ing the grow­ing opi­oid ad­di­tion cri­sis in the US, the FDA’s ad­vi­so­ry com­mit­tee vot­ed 18-1 that RBP-6000 could ben­e­fit ad­dicts. Reg­u­la­tors usu­al­ly fol­low the rec­om­men­da­tions of these com­mit­tees, and the FDA is due to de­cide on the drug by Nov. 30.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER